

Autodisplay Biotech

A proprietary expression platform for the display of heterologous proteins or peptides on the surface of *Escherichia coli*.

THE PRODUCT “Anything from simple peptides to complex proteins can be presented on the surface of *E. coli* using the Autodisplay technology. The advantages are that the proteins on the surface are immobilised and stabilised; they are fully accessible, and multimerization or aggregation of multi-protein complexes is possible. In addition, protein purification is very easy, the DNA is an internal label and *E. coli* is self replicating. Each *E. coli* could express a different protein on its surface, so the technology can be used

Location: Düsseldorf


When founded: 2008

Number of employees: Six

Funding: Sirius Venture Partners is lead investor, KfW and private parties are co-investors.

Collaborations: With several SMEs and research institutes. Participation in public funding programs.


Website: autodisplay-biotech.com



for screening—target structures can be selected using analytical methods such as fluorescence activated cell sorting (FACS). Applications include biocatalysis, drug discovery, bioanalytics and antibody development.

—RUTH MAAS, CEO

FOUNDERS & ORIGINS Autodisplay Biotech is a spin-off from the Heinrich-Heine University Dusseldorf. The founders were Joachim Jose, Head of the Institute of Pharmaceutical and Medicinal Chemistry, Ruth Maas, Group Leader at the same institute, and the founding angel Gunter Festel. All three had previously founded successful companies.



The name is taken from the core technology.